BRCA2 and triple-negative breast carcinoma: To test this we selectively targeted the BRCA1 and BRCA2 loci in the HRR proficient triple negative breast cancer cell line MDA-MB-231 (M231wt), using standard CRISPR-Cas9 techniques [28] to generate an isogenic cell line panel.